Radionuclide Therapy for Neuroendocrine Malignancies

Patient Population

Neuroendocrine cancer patients who are inoperable, or have residual disease following surgery or other ablative therapy, or have metastases.

Intended Guideline Users

Nuclear medicine physicians, medical oncologists, surgeons, and pathologists who are involved in the treatment of the above-targeted patients.

Research Question(s)

1. What are the effects of the eight commonly used and studied therapeutic radiopharmaceuticals described in Table 1 in patients with different types of neuroendocrine malignancies?
2. Which one of the eight therapeutic radiopharmaceuticals is most effective in improving clinical outcomes (i.e., tumour response, duration of tumour response, overall survival [OS] time/rate, progression-free survival [PFS] time/rate, biochemical response, and quality of life [QOL]) in the above patients?
3. What are the toxicities for each therapeutic radiopharmaceutical?